Loading clinical trials...
Loading clinical trials...
An Open-label Phase 1/2a Study of BAL101553 Administered as Intravenous 48-hour Infusions in Adult Patients With Advanced Solid Tumors or Recurrent Glioblastoma
Conditions
Interventions
BAL101553
BAL101553 at MTD
Locations
6
Switzerland
Oncology Institute of Southern Switzerland; Ospedale Regionale San Giovanni Bellinzona e Valli
Bellinzona, Switzerland
Inselspital Bern
Bern, Switzerland
Cantonal Hospital of Grisons, Department of Oncology/ Haematology
Chur, Switzerland
Centre Hospitalier Universitaire Vaudois
Lausanne, Switzerland
Cantonal Hospital of St. Gallen, Dep. Medical Oncology & Hematology
Sankt Gallen, Switzerland
UniversitaetsSpital Zürich
Zurich, Switzerland
Start Date
August 24, 2016
Primary Completion Date
August 7, 2020
Completion Date
August 7, 2020
Last Updated
May 10, 2023
NCT00026884
NCT07159659
NCT07213804
NCT07169851
NCT07191730
NCT06662786
Lead Sponsor
Basilea Pharmaceutica
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions